Xencor, Atreca to work on T cell-based cancer therapies

By The Science Advisory Board staff writers

July 8, 2020 -- Biopharmaceutical company Xencor and biotechnology company Atreca have entered into a license agreement to research, develop, and commercialize T cell-engaging bispecific antibodies as potential cancer therapies.

Bispecific antibodies that direct T cells to tumor cells, by simultaneously binding CD3 on T cells and a target on tumor cells, have the potential to kill tumors. Xencor's engineering platform XmAb will design and manufacture CD3 bispecific antibodies and Atreca's discovery platform, including its immune repertoire capture technology, will be used to generate novel antibody-target pairs.

Their agreement calls for a three-year discovery program with each company. They will work on two programs together, and each can work on two programs separately.

Cancer Research UK, Abcam partner on cancer antibodies
Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used...
Intravacc, CimCure partner on cancer, COVID-19 vaccines
Intravacc has entered a strategic partnership with CimCure for in-licensing of CimCure's iBoost technology for cancer immunotherapy vaccines and a COVID-19...
Biocare Medical, Bethyl Laboratories partner for antibody development
Biocare Medical has formed a strategic partnership with Bethyl Laboratories to develop targeted antibodies for cancer research.
FDA debuts website for patient-reported cancer outcomes
The U.S. Food and Drug Administration (FDA) has unveiled Project Patient Voice, a new pilot program for communicating patient-reported outcomes from cancer...
Researchers discuss progress toward personalized cancer vaccines
Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized...

Copyright © 2020 scienceboard.net

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter